U.S. Markets closed

Neurocrine Biosciences, Inc. (NBIX)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
47.35+0.23 (+0.49%)
At close: 4:00PM EDT
People also watch
ALKSPGNXLGNDNKTRINCY
  • Got a great report from http://jcharlesassets.com/opiant-pharmaceuticals/?s=NBIX about $NBIX. I did have to subscribe but it was worth the time. Thank you guys for the tip! "rht" Trading stocks investing.

    Best Penny, OTC Stocks and Dividend Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
    jcharlesassets.com
  • Like buying NBIX below $3 in 2010
    (AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ....GLTA ! Please readand realize the brutal potential !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • Happiness depends upon ourselves.http://dataunion.tistory.com/9196

    Neurocrine Biosciences NASDAQ $NBIX Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.7 In other words, the correlation coefficient of the other stoc
    dataunion.tistory.com
  • Good chance we see 39 within the next 2 weeks, its a buy at that point boys, just hang on here.
  • The Wolf has returned to pounce on nbix yet again!. Nbix is the gift that just keeps on giving, it gives me shares in the low 40s, then I sell it in the mid 50s!
  • My plan to buy at $25 is looking better by the day.
  • This happened twice due to TS failure in adults and then children. The ingrezza deserves a stable rate at 52-54. So it will be back to those levels once we start getting the stats on prescriptions count👍👍👍
  • Houston...you have a
    problem.
  • bottom has been hit, we will work our way back to 50-55.

    shorts should be covering
  • 47.26 in March..... after approval of Ingrezza, few weeks after approval, today 5/26.. $47.16.... Happens all over Biotech.. SRPT 60 after conditional approval... now 30.
    I've had Nbix a long time and a fairly large position. Can't help but think of the market as a casino without the free drinks... hard to be an investor...... makes more sense to be a momentum player or flipper.
  • One more quick point, the TS news was of course a disappointment, but let's not look past the potential for TD:

    Approx. 500,000 sufferers of TD in the US
    Approx. 350,000 of these are adults
    Approx. 10% of these suitable for the prescription of Ingrezza (according to a few physician interviews I have read)
    Approx. wholesale price of $50,000 (10% discount assunption from announced $64k)
    Approx. peak sales $1.75 billion

    We are not using outlandish assumptions here, the US opportunity alone is big. We are not even factoring in the Elagolix royalty, this could hit more than $0.5 billion, plus AbbVie does the marketing for us!
  • Almost at $40. who is the clown who said it would never see $44? Will be covering once we hit $40, should be soon.
  • Doctor: Agree. P2 study problem is dosing issue. Not efficacy. Dosing needs tweaking. Nothing changed. Strong partnership (ABBV). Good balance sheet. Institutional support. Disruptive technology. Buy the dip. & Relax
  • Surely an over reaction?

    Even if Ingrezza is only ever approved for TD we should be pricing higher than this.
  • NBIX is down -7.25% to 42.87
  • very concerned that this is a pump and dump situation......major drop after earnings then almost a 9% pop back in 4 days???
    as a potential new investor seems like a sucker rally
  • so much for 65 and 70
    May be next year
  • This is ridiculous
  • When they released that PR saying that they were going to report data at the upcoming conference, I was sure this was in the bag - I even added a little at 52. Well...market is being fairly gentle about this after hours...that's encouraging. Also, I personally believe the explanation about dosing, and that this just needs a little tinkering to get right. I was really counting on this one, though. Biotech has been rough lately.
  • I read that article out today - found in the summary section - and learned something I didn't know. TD is currently controlled by benzodiazapines - xanax and the like - and ever-increasing doses have to be used.
    That is absolutely horrible. Benzos eventually turn into a total nightmare for many people using them long term - even under the strictest supervision. I've been through it and it's awful...they seem benign at first, but when you stop you can really be in trouble. It takes a long to get over them, and it's not pretty.
    This makes me feel even better about being invested in NBIX - Ingrezza is a major improvement for people already suffering.
    I started out in biotech by investing in Gilead, and pricing controversy aside, I was proud to be investing in a company eradicating a miserable disease. This is what makes biotech great.